SCHEMBL5847756

SCHEMBL5847756

CCc1nn2ccccc2c1C(C)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 2/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
ALDH1A1 P00352 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
PDE5A O76074 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
TSHR P16473 1/20 0.48
PDE4A P27815 1/20 0.48
ADORA2A P29274 1/20 0.48
ADORA1 P30542 1/20 0.48
CYP2C19 P33261 1/20 0.48
BLM P54132 1/20 0.48
PDE4B Q07343 1/20 0.48
PDE4C Q08493 1/20 0.48
PDE4D Q08499 1/20 0.48
PDE3B Q13370 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7374042 0.88 EGFR (0.49) MIFMEN1KMT2AALDH1A1NPSR1
SCHEMBL2035471 0.88 EGFR (0.48) MIFMEN1KMT2AALDH1A1NPSR1
SCHEMBL683926 0.86 MIF (0.50) MIFMEN1KMT2AALDH1A1NPSR1
SCHEMBL38666633 0.84 EGFR (0.48) MIFMEN1KMT2AALDH1A1NPSR1
SCHEMBL11721382 0.84 MIF (0.54) MIFMEN1KMT2AALDH1A1NPSR1
SCHEMBL5847839 0.83 MIF (0.41) MIFMEN1KMT2AALDH1A1NPSR1
SCHEMBL5847833 0.83 MIF (0.41) MIFMEN1KMT2AALDH1A1NPSR1
SCHEMBL5847842 0.83 MIF (0.41) MIFMEN1KMT2AALDH1A1NPSR1
SCHEMBL1780786 0.82 EGFR (0.53) MIFMEN1KMT2AALDH1A1NPSR1
SCHEMBL20181600 0.81 MIF (0.43) MIFMEN1KMT2AALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151109-B2 Pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators PHARMACIA & UPJOHN COMPANY LLC (US) 2006-12-19 US disclosed
EP-1485384-A1 PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS Pharmacia & Upjohn Company LLC (US) 2004-12-15 EP disclosed
US-20040002511-A1 Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators PHARMACIA & UPJOHN COMPANY 2004-01-01 US disclosed
WO-2003078435-A1 PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS PHARMACIA & UPJOHN COMPANY LLC (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002511-A1 Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators CRHR1, HTR5A, CRH MIF 1152/4885MEN1 2785/4885KMT2A 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.